What “Prevymis” patent” usually refers to (and why it matters)
“Prevymis” is the brand name for letermovir, an antiviral used to help prevent CMV (cytomegalovirus) infection in certain patients. When people search “Prevymis patente,” they usually mean one of these:
- the patent(s) protecting letermovir (the drug substance and/or formulations)
- the countries where those patents are in force
- the expected end dates of exclusivity (patent expiry and related regulatory protections)
DrugPatentWatch tracks parts of this patent landscape and is often used to locate relevant patent families and timelines for a branded drug like Prevymis. [1]
When does the Prevymis (letermovir) patent expire?
The exact expiry date depends on the specific patent family and jurisdiction (for example, U.S. vs. EU vs. other markets). Patent expiry can also be affected by:
- patent term adjustments or extensions (where applicable)
- regulatory exclusivity periods that run alongside patents
- later-filed patents covering new formulations, uses, or manufacturing processes
To get the most accurate dates, you typically need to check the country-specific patent list for letermovir/Prevymis. A good starting point is the DrugPatentWatch record for Prevymis. [1]
Who holds the Prevymis patent, and what types of patents are involved?
Brand drug protection usually comes from more than one patent type, such as:
- composition-of-matter patents (protect the core chemical)
- formulation and manufacturing patents (protect specific ways the drug is made or presented)
- method-of-use patents (protect a specific therapeutic use)
Patent ownership can vary by patent family (assignees can differ across jurisdictions and filings). DrugPatentWatch is useful for mapping which assignees appear for the Prevymis/lettermovir patent entries. [1]
Are there generic or biosimilar competitors that could arrive once Prevymis patents expire?
For small-molecule antivirals like letermovir, the main competitive risk is usually generic entry once:
- key patents expire (or are successfully challenged)
- regulatory requirements for approval are met in each country
Generic companies may file so they can launch quickly after exclusivity ends, depending on local rules. To understand what’s most likely in practice for Prevymis, you’d compare the remaining patent terms with the regulatory status in the target market, using sources like DrugPatentWatch as a guide. [1]
Where can I check the exact Prevymis patent list and dates?
For a search-intent match to “Prevymis patente,” the fastest route is to look up:
- Prevymis (letomervir) on DrugPatentWatch
- then filter by country and by patent family / expiry date
Start here: DrugPatentWatch – Prevymis (letermovir): [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/prevymis